The global oxytocin market is expected to grow at a CAGR of 9.5% during the forecast period. Market growth is driven by increasing birth rates in developing economies, rising awareness regarding maternal healthcare, growing institutional deliveries, and expanding government initiatives aimed at reducing maternal mortality. Oxytocin remains one of the most widely used medications in obstetric care for labor induction, labor augmentation, and prevention of postpartum hemorrhage.
The chemoinformatics market is expected to grow at a CAGR of 15.6% during the forecast period of 2025 to 2033. It is a crucial component of the pharmaceutical and chemical industries, is poised for substantial growth from 2025 to 2033. This expansion is driven by several key factors, including advancements in chemical analysis, drug discovery, and molecular modeling. The market plays a pivotal role in streamlining research processes, reducing costs, and accelerating the development of new compounds.
The healthcare decision support and IBM Watson market is projected to showcase steady growth at a compounded annual growth rate (CAGR) of 11.4% during the forecast period from 2018 to 2026. IT-healthcare segment has undergone tremendous revolution in the last decade providing solutions such as pharmacovigilence, clinical data management, regulatory affairs, scientific journal publications etc.
The antimicrobial susceptibility test market had market size of US$ 2885.42 Mn in 2021 and will grow at a CAGR 4.7% and is anticipated to reach US$ 4354.68 Mn in 2033. World Health Organization (WHO) has stipulated stringent guidelines to life science industry and agriculturists to judiciously use antibiotics. Rising prevalence of infectious disease and looming threat of superbug infection drives the antimicrobial susceptibility market growth.
The global cDNA and oDNA microchips market is growing effectively, was valued at US$ 547.2 Mn in 2020 and expected to reach US$ 1254.0 Mn by 2029. The global market is growing productively at a CAGR of 9.7% during the forecast period. Incorporation of new technologies in the biological and electronic component of microchips is enhancing the overall growth globally. Advancement in nanotechnology, clinical diagnostics, cancer research, and agriculture also reflects favorable growth during the forecast period. High global prevalence of cancer provides major opportunity in the global market.
The global proteomics market held US$ 19.81 Bn in 2020 and expected to grow at compound annual growth rate (CAGR) of 10.4% during the forecast period from 2021 to 2029. The market is fueled by the growing importance of sensitive and accurate diagnosis offered by proteomics in personalized medicine. Detailed study of proteins provides superior understanding and opportunities for the development of drugs that can target disease pathways more efficiently.
The global Medical biosensors market is growing productively, was valued at US$ 9.2 Bn in 2017 and expected to reach US$ XX Bn by 2026. New technology assessment in the biological and electronic component of a biosensor in the portable devices is enhancing the overall growth significantly.
Computational biology is an interdisciplinary science that is being persistently advancing through the previous decades by using the power of mathematics and computation. The primary aim of computational biology is to employ large-scale computational methods to the fields of cellular, structural and molecular biology for answering emerging biological questions which were earlier not possible to be tackled with traditional approaches.
The cell surface markers market is set to reach US$ 33,712.7 Mn by 2026 from US$ 16,586.7 Mn in 2017 showcasing progressive growth at a compound annual growth rate (CAGR) of 8.2% during the forecast period from 2018 to 2026. Technological advancements in the production of monoclonal antibodies and manufacturing of cell specific antibodies for disease diagnosis and prognosis are the major factors to drive the cell surface markers market.
The global artificial intelligent (AI) in healthcare market is primarily driven by the increasing usage of big data in healthcare sector and advantage of AI to improve the imbalance among the healthcare professionals and patients, augment patient outcomes and aid in clinical trial simulation and development process.
The drug discovery market includes research technologies, services and processes used to identify and develop potential therapeutic compounds. The discovery process generally covers target identification, target validation, hit identification, high-throughput screening, lead generation, lead optimization and preclinical candidate selection. The market serves pharmaceutical companies, biotechnology firms, contract research organizations, academic institutes and government research centres.
The global drug discovery market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 78.51 billion in 2026 to USD 171.36 billion by 2035, representing a compound annual growth rate of 9.07%. North America held the largest regional share in 2025, while Asia-Pacific is expected to record the fastest growth. Small molecules remained the leading drug type, and pharmaceutical companies represented the primary end-user group.
Increasing incidence of cancer, diabetes, cardiovascular disorders, neurological conditions, infectious diseases and rare diseases is supporting demand for new therapies. Pharmaceutical and biotechnology companies are investing in research programs to expand development pipelines and replace revenue from products approaching patent expiry. Growth in precision medicine, immunotherapy, cell and gene therapy and RNA-based treatments is also creating demand for advanced discovery platforms.
Artificial intelligence and machine learning represent major market trends. These technologies are being applied to disease-target selection, molecular design, compound screening, toxicity prediction and drug repurposing. Computational approaches can analyse large biological and chemical datasets, helping researchers prioritize promising candidates before laboratory testing. However, AI-generated findings still require experimental validation and supporting clinical evidence.
High-throughput screening, automated laboratories, genomic analysis, proteomics and advanced imaging are improving the speed and quality of early-stage research. Three-dimensional cell cultures, organoids and organ-on-chip systems are being evaluated as alternatives or supplements to conventional laboratory models. These technologies may provide more relevant information about human biological responses during candidate selection.
Outsourcing is also expanding as drug developers work with contract research organizations and specialist technology providers. External partners can provide compound libraries, assay development, medicinal chemistry, toxicology and computational services. Outsourcing allows smaller biotechnology companies to access advanced capabilities without maintaining extensive internal infrastructure.
Market development may be restrained by high research costs, lengthy development timelines and the substantial failure rate of early drug candidates. Limited availability of high-quality biological data and difficulty reproducing research results can affect program outcomes. Intellectual-property concerns, data security and regulatory uncertainty regarding AI-based research tools create additional challenges.
Acute Market Reports provides drug discovery market research covering discovery stages, technologies, drug types, therapeutic areas, service providers, end users, competition and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, CROs and investors evaluate technology adoption, research demand and growth prospects through 2035.